Usted buscó: measurable concentration (Inglés - Maltés)

measurable disease *
marda li tista’ titkejjel

patients with measurable disease
pazjenti b’marda li tista’ titkejjel

measurable, reportable and verifiable
miżurabbli, notifikabbli u verifikabbli

2.1 ambitions and measurable targets
2.1 ambizzjonijiet u miri li jistgħu jitkejlu

secondly, measurable targets are essential.
it-tieni, huwa kruċjali li jiġu stipulati għanijiet li jistgħu jitkejlu.

measurable, achievable, relevant and timed.
li jistgħu jitkejlu, li jistgħu jintlaħqu, relevanti u f’waqthom.

a patients with measurable disease at baseline
a pazjenti b’marda li tista titkejjel fil-linja bażi

5 patients with measurable disease at baseline.
5 pazjenti b’marda li tikejjel fil-lija bażi.

1 in patients with measurable disease at baseline.
1 pazjenti b’marda li setgħet tikejjel fil-linja bażi.

they must be measurable based on predefined indicators;
iridu jitkejlu fuq il-bażi ta’ indikaturi definiti minn qabel;

response rates (for patients with measurable disease)
rati ta’ rispons (għall-pazjenti b’marda li tista’ titkejjel)

specific, measurable, achievable, relevant and time-related
speċifiku, li jista' jitkejjel u jinkiseb, realistiku u marbut mal-ħin

contained no measurable eu objectives concerning target groups; and
ma jinkludux għanijiet miżurabbli tal-ue mmirati lejn gruppi partikolari;

intravenous administration of bivalirudin produces measurable anticoagulation within minutes.
l-għoti minn ġol-vini ta’ bivalirudin jipproduċi antikoagulazzjoni miżurabbli fi ftit minuti.

area under the concentration time curve from 0h data point up to last measurable
auc( 0- tlast) = erja taħt il- kurva tal- konċentrazzjoni vs ħin mill- punt ta ’ tagħrif 0h sa l- aħħar livell fis- serum li jista ’ jitkejjel cv = koeffiċjent ta ’ varjazzjoni

plasma concentrations remain measurable for several months after each zypadhera injection.
il-konċentrazzjonijiet fil- plażma jistgħu jibqgħu jitkejlu għal ħafna xhur wara kull injezzjoni ta’ zypadhera.

measurable in neutral points, 3. comparable between companies, 4.
titkejjel f'punti newtrali, 3. komparabbli bejn il-kumpaniji, 4.

4.3.4 question 20: (ii): no objectively measurable criteria.
4.3.4 mistoqsija 20: (ii): l-ebda kriterji mkejla b’mod oġġettiv.

of the samples that had measurable concentrations 90% had retapamulin concentrations less than 2.5 ng/ml.
mill-kampjuni li kellhom konċentrazzjonijiet li jistgħu jitkejlu 90% kellhom konċentrazzjonijiet ta’ retapamulin ta’ inqas minn 2.5 ng/ml.

the intranasal dosing of 110 micrograms once daily does not typically result in measurable plasma concentrations (<10 pg/ml).
110 mikrogrammi fl-imnieħer darba kuljum ma jirriżultax tipikament f’konċentrazzjonijiet ta’ plażma li jistgħu jitkejlu (< 10 pg/ml).